Public Health, Epidemiology and Health Economics Department, University of Liège, Belgium, Liège, Belgium.
Osteoporos Int. 2014 Jan;25(1):393-5. doi: 10.1007/s00198-013-2437-z. Epub 2013 Jul 9.
Osteonecrosis of the jaw (ONJ) is a clinical condition associated with long-term exposure to inhibitors of bone resorption, mainly bisphosphonates. Denosumab (DMab) is a human monoclonal antibody of the receptor activator of nuclear factor kappa-B ligand. It prevents osteoclast-mediated bone resorption and is widely prescribed for the management of postmenopausal osteoporosis. Whereas ONJ has already been reported in women treated with DMab, we report for the first time the development of ONJ, following tooth extraction, in a male patient treated for idiopathic osteoporosis with DMab. Due to the constant increase in DMab prescription, for the management of osteoporosis, in both genders, physicians should be made aware of this potential risk.
颌骨骨坏死（ONJ）是一种与长期使用骨吸收抑制剂相关的临床病症，主要是双膦酸盐。地舒单抗（DMab）是一种核因子 κB 配体受体激活剂的人源单克隆抗体。它可防止破骨细胞介导的骨质吸收，广泛用于治疗绝经后骨质疏松症。尽管已有使用 DMab 治疗的女性患者发生 ONJ 的报道，但我们首次报告了一名男性特发性骨质疏松症患者在使用 DMab 治疗后拔牙后发生 ONJ。由于 DMab 处方量不断增加，用于治疗男女两性的骨质疏松症，医生应该意识到这种潜在风险。
